A Phase 1/2 interventional study of Navitoclax and Vistusertib in Metastatic Malignant Solid Neoplasm, Recurrent Lung Small Cell Carcinoma and Recurrent Malignant Solid Neoplasm, sponsored by National Cancer Institute (NCI). Terminated at 14 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-10-17.
Sponsored by National Cancer Institute (NCI) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 124 studies in Neoplasm Metastasis by National Cancer Institute (NCI) — 18 open to participants now, 43 under way, none of them phase 3. Neoplasm Metastasis · National Cancer Institute (NCI).
Among the 124 studies in Neoplasm Metastasis by National Cancer Institute (NCI), this one is the 87th largest by enrollment of the 112 interventional ones that give a count, is one of 8 that started in 2018, is one of 18 in phase 1/2, and was the 85th registered.
4,052 studies on the registry are indexed under Neoplasm Metastasis; 893 are open to participants now.
Browse Neoplasm Metastasis studies →18 of the 124 studies in Neoplasm Metastasis by National Cancer Institute (NCI) are open now, in 3 countries. Recruiting first, the newest first:
National Cancer Institute (NCI) · Sites in United States
Ages 18+
National Cancer Institute (NCI) · Sites in United States
Ages 18+
National Cancer Institute (NCI) · Sites in United States
Ages 18+
National Cancer Institute (NCI) · Sites in United States
Ages 18+
National Cancer Institute (NCI) · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 693 Neoplasm Metastasis studies recruiting now, 541 (78%) set no upper age limit and 96 (14%) stop at 75 or younger; 47 take children under 18; 18 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
124 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 88 · Phase 2 47
First in 1984; this study’s year is marked. 8 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 15 is below the median of 50 across 3,275 interventional studies indexed under Neoplasm Metastasis.
Median enrollment 37 across the 112 interventional studies, 408 across the 7 observational. Of the 73 that completed or were terminated, 29 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
National Cancer Institute (NCI) is the lead sponsor of 3,557 studies on the registry; 335 are open to participants now.
Of its 412 completed or terminated interventional studies of FDA-regulated products, 374 (91%) have results posted.
19 of the studies in Neoplasm Metastasis by National Cancer Institute (NCI) that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02862275National Cancer Institute (NCI)Atezolizumab in Treating Patients With Cancer Following Adoptive Cell Transfer | 2026-11-21 |
| NCT03030378National Cancer Institute (NCI)Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors | 2026-12-01 |
| NCT04585958National Cancer Institute (NCI)Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer | 2026-12-31 |
| NCT05327010National Cancer Institute (NCI)Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial | 2026-12-31 |
| NCT06606990National Cancer Institute (NCI)Testing How the Body Responds to the Drug CX-5461 (Pidnarulex) in Patients With Metastatic Solid Cancers | 2026-12-31 |
Add all 19 to your calendar (.ics) → With an account.
Among the 124 studies in Neoplasm Metastasis by National Cancer Institute (NCI), from their registry updates:
This tab as a report to print or save as PDF → With an account.
This phase I/II trial studies the best dose and side effects of navitoclax and how well it works when given together with vistusertib in treating patients with small cell lung cancer and solid tumors that have come back (relapsed). Drugs used in chemotherapy, such as navitoclax, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Vistusertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving navitoclax and vistusertib may work better than navitoclax alone in treating patients with small cell lung cancer and solid tumors.
PRIMARY OBJECTIVES:
I. To evaluate the safety and tolerability of the combination of navitoclax and vistusertib in patients with advanced solid tumors. (Phase I) II. To determine the maximum tolerated dose (MTD), dose limiting toxicities (DLT), and recommended phase 2 doses (RP2D) of navitoclax and vistusertib. (Phase I) III. To determine the objective response rate (ORR), defined as complete plus partial response, of the combination of navitoclax and vistusertib in patients with recurrent small cell lung cancer (SCLC). (Phase II)
SECONDARY OBJECTIVES:
I. To evaluate the pharmacokinetics of navitoclax and vistusertib when administered together. (Phase I) II. To observe and record anti-tumor activity. (Phase I) III. To confirm the safety and tolerability of navitoclax and vistusertib at the RP2D. (Phase II) IV. To estimate progression free survival (PFS) and overall survival (OS) of the combination of navitoclax and vistusertib at the RP2D. (Phase II) V. To estimate disease control rate (DCR) of the combination of navitoclax and vistusertib at the RP2D. (Phase II)
CORRELATIVE OBJECTIVES:
I. To assess pharmacodynamic changes in levels of phosphorylated 4EBP1 (p4EBP1) the ratio of p4EBP1 to total (p4EBP1/4EBP1) in paired pre-treatment and on-treatment biopsies at the RP2D. (Phase II) II. To correlate changes in BAX and MCL-1 with response. (Phase II) III. To estimate the baseline inter-patient variability in p4EBP1, pS6, BAX, and MCL-1. (Phase II) IV. To explore exposure-response relationships between navitoclax and vistusertib exposure and the pharmacodynamic endpoints (safety, efficacy, and laboratory correlatives). (Phase II)
OUTLINE: This is a phase I, dose-escalation study followed by a phase II study.
Patients receive navitoclax orally (PO) once daily (QD) and vistusertib PO twice daily (BID) on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up for 30 days and then every 8-12 weeks for up to 2 years.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The effects of navitoclax and vistusertib on the developing human fetus are unknown; for this reason, women of and men must agree to use adequate prior to study entry, for the duration of study participation, and up to 90 days following completion of therapy; for women this should include one highly effective method of contraception and one barrier method as defined below
Highly effective methods include:
Barrier methods include:
Exclusion Criteria:
Patients receiving anticoagulation or anti- therapy are excluded due to the risk of thrombocytopenia with navitoclax
Any of the following cardiac criteria:
Patients currently receiving medications or herbal supplements of the classes below are ineligible; patients are eligible if they stop use of these compounds at least 1 week prior to receiving any treatment on this protocol
Patients positive for (HIV) are not excluded from this study, but HIV-positive patients must have:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients receive navitoclax PO QD and vistusertib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Biological: Navitoclax · Drug: Vistusertib
Given PO
Also known as: A-855071.0, ABT-263, BcI-2 Family Protein Inhibitor ABT-263
Given PO
Also known as: AZD 2014, AZD-2014, AZD2014
Number of Participants With Dose Limiting Toxicities (Phase I)
Graded by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version (v) 4.0. The number of participants with dose limiting toxicities at each dose level will be reported with exact binomial 95% confidence intervals. All patients who receive at least 1 dose of both study drugs, regardless of their eligibility for the study, will be evaluable for toxicity.
Time frame: Up to 30 days after last treatment, an average of 3 months
Overall Response Rate (ORR) (Phase II)
Defined as Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. partial response or complete response, of the combination in patients with recurrent small cell lung cancer. The ORR will be reported with its corresponding 95% confidence interval.
Time frame: Up to 1.5 years
Occurrence of a Bi-directional Pharmacokinetic (PK) Interaction
Concentrations of each study agent present in the blood at the specified time point are reported for each study agent.
Time frame: Through Day 15
Number of Participants Experiencing Adverse Events by Grade (Phase II)
Graded by NCI CTCAE v 4.0. The number of participants with toxicities by grade in the phase 2 study will be reported with exact binomial 95% confidence intervals.
Time frame: Up to 1.5 years
Progression Free Survival (PFS) (Phase II)
Based on RECIST 1.1. Standard life table methods will be used to analyze PFS. We will report the one-year and median PFS with 95% confidence intervals.
Time frame: Up to 1.5 years
Overall Survival (OS) at Year 1 (Phase II)
Standard life table methods will be used to analyze OS. We will report the one-year and median OS with 95% confidence intervals.
Time frame: At Year 1
Disease Control Rate (Phase II)
Based on RECIST 1.1. The proportion of patients achieving disease control will be reported with exact 95% binomial confidence intervals.
Time frame: Up to 1.5 years
Change in p4EBP1 Expression
Descriptive statistics and box plots with jittered data points will be used to visualize all raw data. Will be assessed with paired t-tests.
Time frame: Baseline up to 1.5 years
Change in Ratio p4EBP1/4EBP1
Descriptive statistics and box plots with jittered data points will be used to visualize all raw data. Will be assessed with paired t-tests.
Time frame: Baseline up to 1.5 years
Change in Ratio pS6/S6
Descriptive statistics and box plots with jittered data points will be used to visualize all raw data. Will be assessed with paired t-tests.
Time frame: Baseline up to 1.5 years
Change in BAX and MCl-1 Expression
Descriptive statistics and box plots with jittered data points will be used to visualize all raw data. Will be assessed with paired t-tests.
Time frame: Baseline up to 1.5 years
Pharmacodynamic Parameters
Exploratory correlative studies with pharmacodynamic (biological endpoints, toxicity and efficacy) will be analyzed using nonparametric statistics.
Time frame: Up to 1.5 years
Phase 1: 03/20/2018 - 11/11/2019 Phase 2: 7/29/2020 - 5/19/2021
| Milestone | Phase 1 - Dose Level 1 | Phase 1 - Dose Level 2 | Phase 2 |
|---|---|---|---|
| Started | 9 | 5 | 1 |
| Completed | 6 | 3 | 1 |
| Not completed | 3 | 2 | 0 |
| Withdrew: Disease progression | 3 | 1 | 0 |
| Withdrew: Adverse event | 0 | 1 | 0 |
Graded by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version (v) 4.0. The number of participants with dose limiting toxicities at each dose level will be reported with exact binomial 95% confidence intervals. All patients who receive at least 1 dose of both study drugs, regardless of their eligibility for the study, will be evaluable for toxicity.
| Participants | Phase 1 - Dose Level 1 | Phase 1 - Dose Level 2 |
|---|---|---|
| DLT | 0 | 2 |
| No DLT | 6 | 1 |
Defined as Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. partial response or complete response, of the combination in patients with recurrent small cell lung cancer. The ORR will be reported with its corresponding 95% confidence interval.
| Participants | Phase 2 |
|---|---|
| Partial Response (PR) or Complete Response (CR) | 0 |
| Stable Disease (SD) | 0 |
| Progression (PD) | 1 |
Concentrations of each study agent present in the blood at the specified time point are reported for each study agent.
| ng/ml | Navitoclax 150 mg + Vistusertib 35 mg | Navitoclax 250 mg + Vistusertib 35 mg | Navitoclax 250 mg Reduced to 150 mg + Vistusertib 35 mg |
|---|---|---|---|
| Navitoclax average of individual steady-state trough concentration (avg Cmin,ss) | 1145 ± 289 | 1966 ± 999 | 2283 |
| Navitoclax Cycle 1 Day 1 Concentration 6 hours after dose (C6h) | 1808 ± 980 | 3254 ± 1233 | — |
| Navitoclax Cycle 1 Day 15 Concentration 6 hours after dose (C6h) | 2260 ± 993 | 2830 ± 1190 | 3450 |
| Navitoclax Cycle 1 Day 15 maximum concentration (Cmax) | 2393 ± 913 | 3060 ± 1070 | 3910 |
| Vistusertib average of individual steady-state trough concentration (avg Cmin,ss) | 211 ± 207 | 559 ± 550 | 238.5 |
| Vistusertib Cycle 1 Day 1 Concentration 2 hours after dose (C2h) | 372 ± 266 | 419 ± 108 | — |
| Vistusertib Cycle 1 Day 15 Concentration 2 hours after dose (C2h) | 1061 ± 675 | 1032 ± 832 | 273 |
Graded by NCI CTCAE v 4.0. The number of participants with toxicities by grade in the phase 2 study will be reported with exact binomial 95% confidence intervals.
| participants | Phase 2 |
|---|---|
| Grade 1 Adverse Events | 1 |
| Grade 2 Adverse Events | 1 |
| Grade 3 Adverse Events | 0 |
| Grade 4 Adverse Events | 0 |
| Grade 5 Adverse Events | 0 |
Based on RECIST 1.1. Standard life table methods will be used to analyze PFS. We will report the one-year and median PFS with 95% confidence intervals.
| Participants | Phase 2 |
|---|---|
| Progression Free Survival (PFS) (Phase II) | 0 |
Standard life table methods will be used to analyze OS. We will report the one-year and median OS with 95% confidence intervals.
| Participants | Phase 2 |
|---|---|
| Overall Survival (OS) at Year 1 (Phase II) | 0 |
Based on RECIST 1.1. The proportion of patients achieving disease control will be reported with exact 95% binomial confidence intervals.
| Participants | Phase 2 |
|---|---|
| Disease Control Rate (Phase II) | 0 |
Descriptive statistics and box plots with jittered data points will be used to visualize all raw data. Will be assessed with paired t-tests.
No measurements were reported for this outcome.
Descriptive statistics and box plots with jittered data points will be used to visualize all raw data. Will be assessed with paired t-tests.
No measurements were reported for this outcome.
Descriptive statistics and box plots with jittered data points will be used to visualize all raw data. Will be assessed with paired t-tests.
No measurements were reported for this outcome.
Descriptive statistics and box plots with jittered data points will be used to visualize all raw data. Will be assessed with paired t-tests.
No measurements were reported for this outcome.
Exploratory correlative studies with pharmacodynamic (biological endpoints, toxicity and efficacy) will be analyzed using nonparametric statistics.
No measurements were reported for this outcome.
Collected over Up to 1.5 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase 1 - Dose Level 1 | 6/9 (66.7%) | 2/9 (22.2%) | 9/9 (100%) |
| Phase 1 - Dose Level 2 | 3/5 (60%) | 2/5 (40%) | 5/5 (100%) |
| Phase 2 | 1/1 (100%) | 0/1 (0%) | 1/1 (100%) |
| Event | Phase 1 - Dose Level 1 | Phase 1 - Dose Level 2 | Phase 2 |
|---|---|---|---|
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 0/9 | 2/5 | 0/1 |
| DyspneaRespiratory, thoracic and mediastinal disorders | 0/9 | 1/5 | 0/1 |
| HypokalemiaMetabolism and nutrition disorders | 0/9 | 1/5 | 0/1 |
| DiarrheaGastrointestinal disorders | 0/9 | 1/5 | 0/1 |
| HypoxiaRespiratory, thoracic and mediastinal disorders | 0/9 | 1/5 | 0/1 |
| Colonic obstructionGastrointestinal disorders | 1/9 | 0/5 | 0/1 |
| Enterocolitis infectiousInfections and infestations | 1/9 | 0/5 | 0/1 |
| Platelet count decreasedInvestigations | 1/9 | 0/5 | 0/1 |
| Blood bilirubin decreasedInvestigations | 1/9 | 0/5 | 0/1 |
| Event | Phase 1 - Dose Level 1 | Phase 1 - Dose Level 2 | Phase 2 |
|---|---|---|---|
| DiarrheaGastrointestinal disorders | 4/9 | 2/5 | 1/1 |
| NauseaGastrointestinal disorders | 3/9 | 3/5 | 1/1 |
| Abdominal PainGastrointestinal disorders | 2/9 | 1/5 | 1/1 |
| DyspepsiaGastrointestinal disorders | 1/9 | 0/5 | 1/1 |
| Non-cardiac chest painGeneral disorders | 1/9 | 0/5 | 1/1 |
| AnorexiaMetabolism and nutrition disorders | 1/9 | 3/5 | 1/1 |
| PruritusSkin and subcutaneous tissue disorders | 1/9 | 0/5 | 1/1 |
| Renal and urinary disordersRenal and urinary disorders | 0/9 | 0/5 | 1/1 |
| Skin disorderSkin and subcutaneous tissue disorders | 0/9 | 0/5 | 1/1 |
| Cognitive disturbanceNervous system disorders | 0/9 | 0/5 | 1/1 |
| Age, Continuous(years) | Phase 1 - Dose Level 1 | Phase 1 - Dose Level 2 | Phase 2 | Total |
|---|---|---|---|---|
| Median | 49 (35 to 74) | 67 (53 to 71) | 77 (77 to 77) | 60 (35 to 77) |
| Sex: Female, Male(Participants) | Phase 1 - Dose Level 1 | Phase 1 - Dose Level 2 | Phase 2 | Total |
|---|---|---|---|---|
| Female | 6 | 3 | 0 | 9 |
| Male | 3 | 2 | 1 | 6 |
| Ethnicity (NIH/OMB)(Participants) | Phase 1 - Dose Level 1 | Phase 1 - Dose Level 2 | Phase 2 | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 8 | 5 | 1 | 14 |
| Unknown or Not Reported | 1 | 0 | 0 | 1 |
| Race (NIH/OMB)(Participants) | Phase 1 - Dose Level 1 | Phase 1 - Dose Level 2 | Phase 2 | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 0 | 1 |
| White | 7 | 4 | 1 | 12 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 0 | 1 |
| Region of Enrollment(participants) | Phase 1 - Dose Level 1 | Phase 1 - Dose Level 2 | Phase 2 | Total |
|---|---|---|---|---|
| United States | 9 | 5 | 1 | 15 |
| Weight(kg) | Phase 1 - Dose Level 1 | Phase 1 - Dose Level 2 | Phase 2 | Total |
|---|---|---|---|---|
| Median | 75 (58.5 to 86.8) | 68.5 (56.6 to 114.4) | 86.2 (86.2 to 86.2) | 75 (56.6 to 114.4) |
| Height(cm) | Phase 1 - Dose Level 1 | Phase 1 - Dose Level 2 | Phase 2 | Total |
|---|---|---|---|---|
| Median | 167.6 (162.6 to 188.0) | 165.0 (162.5 to 178.0) | 172.7 (172.7 to 172.7) | 167.6 (162.5 to 188) |
| Body Surface Area (BSA)(m^2) | Phase 1 - Dose Level 1 | Phase 1 - Dose Level 2 | Phase 2 | Total |
|---|---|---|---|---|
| Median | 1.90 (1.63 to 2.00) | 1.76 (1.62 to 2.31) | 2.03 (2.03 to 2.03) | 1.9 (1.62 to 2.31) |
2 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Mar 2018 to primary completion in Jul 2021, 40 months.
Results were first posted in May 2023, 1 year 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Navitoclax · Vistusertib
National Cancer Institute (NCI) →